All In Biotech

Drug Trial Radar · NCT00303810

Radiation Therapy and Combination Chemotherapy in Treating Young Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma

Multicenter Therapy Optimizing Study for Treatment of Children and Adolescents With Intracranial Medulloblastoma / PNET and Ependymoma

Last checked: Nov 19, 2026Latest source record: Jan 28, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

567

Actual

Start

Jan 2001

Primary completion

Dec 2013

Sponsor

Lead sponsor
Universitätsklinikum Hamburg-EppendorfAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 17, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Masking
None
Primary purpose
Treatment
Who can join
All sexes, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy in different ways and giving it together with more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known which radiation therapy and combination chemotherapy regimen is more effective in treating medulloblastoma, supratentorial primitive neuroectodermal tumor (PNET), or ependymoma. PURPOSE: This clinical trial is studying six different radiation therapy and combination chemotherapy regimens to compare how well they work in treating young patients with medulloblastoma, PNET, or ependymoma.

Conditions

  • Brain and Central Nervous System Tumors

Interventions

  • carboplatinDrug

  • cisplatinDrug

  • cyclophosphamideDrug

  • etoposide phosphateDrug

  • high-dose chemotherapyDrug

  • lomustineDrug

  • methotrexateDrug

  • thiotepaDrug

  • vincristine sulfateDrug

  • radiation therapyRadiation

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Medical Center Hamburg - Eppendorf

    Hamburg, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.